Form 4: Corcept Therapeutics Chief Business Officer Sells Shares Under Pre-Arranged Plan

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc., sold 3,185 shares of common stock at $70.77 per share on June 16, 2025, as part of a pre-arranged trading plan.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc. (CORT), reported the sale of 3,185 shares of common stock.
• The transaction occurred on June 16, 2025, at a price of $70.77 per share.
• The sale was conducted under a Rule 10b5-1(c) pre-arranged trading plan, indicating it was scheduled in advance.
• Following the transaction, Mr. Robb directly beneficially owns 13,364 shares, which includes 2,082 shares underlying unvested restricted stock awards.
• He also indirectly beneficially owns 23,142 shares through two custodial accounts for his children (11,571 shares in each account).
• The unvested restricted stock awards vest 100% on the one-year anniversary of their respective grant dates (September 3, 2024; December 2, 2024; March 3, 2025; and June 2, 2025), provided certain requirements are satisfied.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a Rule 10b5-1 plan suggests it was a pre-scheduled, routine transaction rather than a reaction to new negative information. The officer also retains significant ownership.

Positives

• The sale was executed under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not based on immediate insider information, which can reduce concerns about opportunistic selling.
• The Chief Business Officer retains significant direct and indirect beneficial ownership in the company, totaling 36,506 shares after the reported transaction.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the officer's direct stake in the company.

Future Outlook

NA

Industry Context

This is a routine insider transaction for a biotechnology/pharmaceutical company. Such filings are common and provide transparency into executive stock ownership and trading activities. They are generally not indicative of broader industry trends unless a pattern of insider selling emerges across multiple companies or within the same company over time.

Related Party Transactions

• Indirect beneficial ownership of 23,142 shares is held through two custodial accounts for the Reporting Person's children, which are considered related party holdings under the Uniform Transfers to Minors Act.

Stakeholder Impact

• Shareholders: Provides transparency into insider trading activity. A pre-planned sale might alleviate concerns about opportunistic selling.

Next Steps

• The unvested restricted stock awards will vest on their respective one-year anniversaries, provided the reporting person satisfies certain requirements.

Key Dates

Keywords

Corcept Therapeutics, CORT, SEC Form 4, Insider Trading, Stock Sale, Gary Charles Robb, Chief Business Officer, Rule 10b5-1, Restricted Stock Awards, Biotechnology, Pharmaceuticals